Begin patient enrollment for Phase 2 safety and efficacy study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 12 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- December 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“patient enrollment anticipated to begin in the second half of the calendar year”
What we found
Evidence strength A What the grades mean
A later 10-K says enrollment and patient treatment began in December 2021, before the year-end deadline. A January 2022 8-K says the Phase 2 trial was initiated in September 2021.
-
A InMed Pharmaceuticals Inc. 8-K filed 2022-01-05
“which we initiated in September of 2021.” ✓ confirmed on the page
-
A InMed Pharmaceuticals Inc. 10-K filed 2022-09-23
“Enrollment and patient treatment began in December 2021 and are expected to complete during the calendar year 2022.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Patient enrollment for Phase 2 study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you InMed Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-INM-023743 · Corrections policy